Dr. Teixeira earned her MD from the Faculdade de Medicina da Universidade do Porto (FMUP) in 2001. In 2024, she was recognized as a European Rare Kidney Diseases Specialist within the ERKNet network and obtained her subspecialisation in Pediatric Nephrology from the Portuguese Medical Council. She currently serves as Consultant in Pediatrics and Pediatric Nephrology at CMIN-ULSSA, where she also coordinates the Pediatric Kidney Transplant Reference Center. In addition, she is HCP lead of the ERN TransplantChild, Co-chair of the CAKUT and Ciliopathies ERKNet Working Group, Co-chair of the Educational Committee of the European Society for Paediatric Nephrology (ESPN), and Co-chair of the Junior Master Class Sub-committee of the International Pediatric Nephrology Association (IPNA).

She has held consultant positions in Pediatrics and Pediatric Nephrology at CMIN-ULSSA since 2017 and has been a long-standing member of its Pediatric Kidney Transplant Reference Center. Between 2010 and 2017, she trained and worked as a Pediatric Assistant and Pediatric Nephrology fellow at Centro Hospitalar Universitário São João, Porto, while also serving as Assistant Teacher of Pediatrics and Pediatric Nephrology at FMUP. Since 2017, she has pursued her PhD at the Instituto de Saúde Pública da Universidade do Porto (ISPUP). She has held several leadership roles, including as a Council Member of IPNA (2020–2023), Chair of the IPNA Juniors Committee (2020–2023), and Council Member of ESPN (2017–2020). She has also been actively involved in multiple committees and working groups of IPNA, ESPN, ERKNet, ERN TransplantChild, and the Portuguese Society of Pediatrics.

Her main research interests focus on chronic kidney disease, cardiovascular risk, and diabetic kidney disease in childhood, as well as national and international registries on ciliopathies (ADPKD and ARPKD), acute kidney injury, and chronic kidney disease. She has contributed to several landmark multicenter studies, including the ESCAPE trial on strict blood pressure control and ACE inhibition, the 4C Study on cardiovascular complications in pediatric CKD, the European PodoNet project on podocyte disorders, and the Predict trial on antibiotic prophylaxis and renal damage in congenital anomalies of the kidney and urinary tract.